Impact of Preceding Respiratory Viral Infections on the Clinical Severity of Patients with Pneumococcal Pneumonia

Overview

Journal Influenza Other Respir Viruses

Publisher Wiley

Specialty Microbiology

Date 2014 Jun 26

PMID 24962523

Citations 4

Authors

Young Kyung Yoon

Kyung Sook Yang

Jang Wook Sohn

Chang Kyu Lee

Min Ja Kim

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the impact of preceding respiratory viral infections (RVI) on the clinical severity of pneumococcal pneumonia patients.

Methods: A retrospective observational study was conducted at a university hospital from January 2009 to March 2013. Study subjects included adults (aged ≥18 years) with pneumococcal pneumonia who had undergone laboratory tests for RVI. Multivariate logistic regression analysis was performed to identify risk factors associated with severe pneumococcal pneumonia, defined as severity with the Pneumonia Severity Index (PSI) score ≥91.

Results: In total, 191 patients with pneumococcal pneumonia were included for analysis and stratified into 2 groups: the severe group with a PSI score ≥91 (n = 99) and the non-severe group with a PSI score <91 (n = 92). Preceding RVIs were detected in 48 patients, including influenza A virus (n = 20), influenza B virus (n = 4), parainfluenza viruses (n = 5), metapneumovirus (n = 4), rhinovirus (n = 4), respiratory syncytial viruses (n = 6), coronaviruses (n = 2), and mixed viral infections (n = 3). In the multivariate logistic regression analysis, preceding RVIs (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.10-5.60), male sex (OR, 2.58; 95% CI, 1.24-5.38), old age (OR, 2.92; 95% CI, 1.37-6.24), hypoalbuminemia (OR, 3.26; 95% CI, 1.56-6.84)], and azotemia (OR, 2.24; 95% CI, 1.08-4.67) were significantly associated with severe pneumococcal pneumonia.

Conclusion: This study suggests that preceding RVIs might be one of the risk factors affecting the clinical severity of pneumococcal pneumonia.

Citing Articles

Interactions among 17 respiratory pathogens: a cross-sectional study using clinical and community surveillance data.

Burstein R, Althouse B, Adler A, Akullian A, Brandstetter E, Cho S medRxiv. 2022; .

PMID: 35169816 PMC: 8845514. DOI: 10.1101/2022.02.04.22270474.

Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration.

Han J, Shi L, Xie Y, Zhang Y, Huang S, Li J Epidemiol Infect. 2020; 148:e125.

PMID: 32580792 PMC: 7332754. DOI: 10.1017/S0950268820001399.

Prevalence and clinical impact of VIral Respiratory tract infections in patients hospitalized for Community-Acquired Pneumonia: the VIRCAP study.

Tatarelli P, Magnasco L, Borghesi M, Russo C, Marra A, Mirabella M Intern Emerg Med. 2019; 15(4):645-654.

PMID: 31786751 PMC: 7088538. DOI: 10.1007/s11739-019-02243-9.

Factors influencing severity of community-acquired pneumonia.

Mahendra M, Jayaraj B, Limaye S, Chaya S, Dhar R, Mahesh P Lung India. 2018; 35(4):284-289.

PMID: 29970765 PMC: 6034384. DOI: 10.4103/lungindia.lungindia_334_17.

References

Johansson N, Kalin M, Hedlund J . Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis. 2011; 43(8):609-15. DOI: 10.3109/00365548.2011.570785. View

Saldias P F, Viviani G P, Pulgar B D, Valenzuela F F, Paredes E S, Diaz P O . [Prognostic factors and mortality in immunocompetent adult patients hospitalized with community-acquired pneumococcal pneumonia]. Rev Med Chil. 2010; 137(12):1545-52. DOI: /S0034-98872009001200001. View

Alymova I, Portner A, Takimoto T, Boyd K, Babu Y, McCullers J . The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2004; 49(1):398-405. PMC: 538863. DOI: 10.1128/AAC.49.1.398-405.2005. View

Song J, Choe P, Song K, Park W, Park S, Kim H . Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. Epidemiol Infect. 2011; 140(7):1267-76. DOI: 10.1017/S0950268811001816. View

van der Poll T, Opal S . Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009; 374(9700):1543-56. DOI: 10.1016/S0140-6736(09)61114-4. View

Kukavica-Ibrulj I, Hamelin M, Prince G, Gagnon C, Bergeron Y, Bergeron M . Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol. 2008; 83(3):1341-9. PMC: 2620891. DOI: 10.1128/JVI.01123-08. View

Rodriguez A, Lisboa T, Blot S, Martin-Loeches I, Sole-Violan J, de Mendoza D . Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2008; 35(3):430-8. DOI: 10.1007/s00134-008-1363-6. View

Johnstone J, Majumdar S, Fox J, Marrie T . Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. 2008; 134(6):1141-1148. PMC: 7094572. DOI: 10.1378/chest.08-0888. View

Harboe Z, Thomsen R, Riis A, Valentiner-Branth P, Christensen J, Lambertsen L . Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009; 6(5):e1000081. PMC: 2680036. DOI: 10.1371/journal.pmed.1000081. View

10.

Stark J, Stark M, Colasurdo G, LeVine A . Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol. 2006; 78(6):829-38. DOI: 10.1002/jmv.20631. View

11.

Charlson M, Szatrowski T, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245-51. DOI: 10.1016/0895-4356(94)90129-5. View

12.

Templeton K, Scheltinga S, van den Eeden W, Graffelman A, van den Broek P, Claas E . Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis. 2005; 41(3):345-51. PMC: 7107904. DOI: 10.1086/431588. View

13.

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

14.

Riquelme R, Torres A, de la Bellacasa J, Estruch R, Mensa J, Fernandez-Sola J . Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med. 1996; 154(5):1450-5. DOI: 10.1164/ajrccm.154.5.8912763. View

15.

Tristram D, Hicks Jr W, Hard R . Respiratory syncytial virus and human bronchial epithelium. Arch Otolaryngol Head Neck Surg. 1998; 124(7):777-83. DOI: 10.1001/archotol.124.7.777. View

16.

Lim W, van der Eerden M, Laing R, Boersma W, Karalus N, Town G . Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377-82. PMC: 1746657. DOI: 10.1136/thorax.58.5.377. View

17.

Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman M, Leiononen M . Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996; 51(2):179-84. PMC: 473032. DOI: 10.1136/thx.51.2.179. View

18.

Feikin D, Schuchat A, Kolczak M, Barrett N, Harrison L, LEFKOWITZ L . Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000; 90(2):223-9. PMC: 1446155. DOI: 10.2105/ajph.90.2.223. View

19.

Jennings L, Anderson T, Beynon K, Chua A, Laing R, Werno A . Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax. 2007; 63(1):42-8. DOI: 10.1136/thx.2006.075077. View

20.

Roh K, Kim J, Nam M, Yoon S, Lee C, Lee K . Comparison of the Seeplex reverse transcription PCR assay with the R-mix viral culture and immunofluorescence techniques for detection of eight respiratory viruses. Ann Clin Lab Sci. 2008; 38(1):41-6. View